PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Embryonal carcinoma

Drugs in development · updated 30 October 2026

Embryonal carcinoma: drugs in development

Rare diseasePrevalence <1 / 1 000 000 according to Orphanet · ORPHA:180226

As of 30 October 2026 there are 2 active clinical trials (recruiting or ongoing, phases I–III) on 9 drugs for embryonal carcinoma. 0 are experimental, that is not yet approved in the United States.

2Active trials
0Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CarboplatinCarboplatine, ParaplatinIII2NCT03067181
EtoposideAvopef®, Etopophos Preservative Free®III2NCT03067181
BleomycinBleomicina, Blenoxane®III1NCT03067181
CisplatinCis Platinum, CisplatineIII1NCT03067181
FilgrastimRecombinant Human Granulocyte Colony-Stimulating Factor, NeupogenII1NCT04684368
IfosfamideII1NCT04684368
MesnaUromitexan, Mesnex®II1NCT04684368
PegfilgrastimArmlupeg®, Stimufend®II1NCT04684368
ThiotepaTepylute®, Tepadina And Sodium Chloride®II1NCT04684368

Sorted by most advanced phase and number of active trials.

All 9 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018236 “Carcinoma, Embryonal”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch